The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/91553-the-proliferation-marker-ki67-but-not-neuroendocrine-expression-is-an-independent-factor-in-the-prediction-of-prognosis-of-primary-prostate-cancer-patients.html
May 14, 2024
4
APCCC 2019: Clinical Utility of Molecular Markers
www.urotoday.com/conference-highlights/apccc-2019/114594-apccc-2019-clinical-utility-of-molecular-markers.html
May 14, 2024
10
EAU Guidelines: Prostate Cancer | Uroweb
uroweb.org/guideline/prostate-cancer/
May 14, 2024
39
Primary adenocarcinoma of ureter: A rare histopathological variant
www.ncbi.nlm.nih.gov/pmc/articles/PMC4944632/
May 14, 2024
4
Is "extreme" bladder neck preservation in robot-assisted radical prostatectomy a safe procedure?
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/118627-is-extreme-bladder-neck-preservation-in-robot-assisted-radical-prostatectomy-a-safe-procedure.html
May 14, 2024
64
The Neuroendocrine Prostate Cancer Spectrum Diagnosis and Treatment Presentation - Eleni Efstathiou
www.urotoday.com/video-lectures/apccc-2019-conference/video/1469-the-neuroendocrine-prostate-cancer-spectrum-diagnosis-and-treatment-presentation-eleni-efstathiou.html
May 14, 2024
41
Disadvantages of PSMA PET/CT in Advanced Prostate Cancer Imaging Presentation - Ian Davis
www.urotoday.com/video-lectures/apccc-2019-conference/video/1506-players-brightcove-net2019-09-29-17-13-04.html
May 14, 2024
132
The Future of Biomarkers in Advanced Prostate Cancer - Mark Rubin
www.urotoday.com/video-lectures/apccc-2019-conference/video/1494-the-future-of-biomarkers-in-advanced-prostate-cancer-mark-rubin.html
May 14, 2024
2
Emacs Doom for Newbies
medium.com/urbint-engineering/emacs-doom-for-newbies-1f8038604e3b
May 14, 2024
32
EAU 2020: Perioperative Therapy for Urothelial Cancer: PD-1/PD-L1 Inhibitors are Replacing Perioperative Chemotherapy
www.urotoday.com/conference-highlights/eau-2020/bladder-cancer/123169-eau-2020-perioperative-therapy-for-urothelial-cancer-pd-1-pd-l1-inhibitors-are-replacing-perioperative-chemotherapy.html
May 14, 2024
13
EAU 2020: What Should You Do with Men You Do Not Biopsy, or Whose Biopsy Is Negative?
www.urotoday.com/conference-highlights/eau-2020/prostate-cancer/123167-eau-2020-what-should-you-do-with-men-you-do-not-biopsy-or-whose-biopsy-is-negative.html
May 14, 2024
7
EAU 2020: Recurrence after Radical Prostatectomy: Summary from the EAU Prostate Cancer Guidelines Panel
www.urotoday.com/conference-highlights/eau-2020/prostate-cancer/123028-eau-2020-recurrence-after-radical-prostatectomy-summary-from-the-eau-prostate-cancer-guidelines-panel.html
May 14, 2024
12
AUA 2020: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in TITAN: Prognostic Importance of Prostate-Specific Antigen Responses
www.urotoday.com/conference-highlights/aua-2020/aua-2020-prostate-cancer/122667-aua-2020-apalutamide-for-metastatic-castration-sensitive-prostate-cancer-in-titan-prognostic-importance-of-prostate-specific-antigen-responses.html
May 14, 2024
2
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
clincancerres.aacrjournals.org/content/25/3/967
May 14, 2024
28
EAU Guidelines: Muscle-invasive and Metastatic Bladder Cancer
uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/
May 14, 2024
8
Non-muscle invasive high grade urothelial carcinoma of the bladder. Which factors can influence understaging at the time of radical cystectomy?
www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/88019-non-muscle-invasive-high-grade-urothelial-carcinoma-of-the-bladder-which-factors-can-influence-understaging-at-the-time-of-radical-cystectomy.html
May 14, 2024
2
Bipolar androgen therapy: Progress and future directions
oncology.medicinematters.com/prostate-cancer/androgen-deprivation-therapy/bipolar-androgen-therapy--progress-and-future-directions/15910622
May 14, 2024
21
APCCC 2019: Pitfalls of PSMA PET-CT in Advanced Prostate Cancer Imaging
www.urotoday.com/conference-highlights/apccc-2019/114600-apccc-2019-pitfalls-of-psma-pet-ct-in-apc-imaging.html
May 14, 2024
6
Could not open /dev/vmmon
forum.manjaro.org/t/could-not-open-dev-vmmon/21431
May 14, 2024
3
ESMO Virtual Congress 2020: The Final Overall Survival (OS) Analysis From the PROfound Study and IPATential150, Ipatasertib Plus Abiraterone (abi) vs Placebo Plus Abi in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Invited Discussion
www.urotoday.com/conference-highlights/esmo-2020/prostate-cancer/124589-esmo-virtual-congress-2020-invited-discussant-lba4-ipatential150-and-610o-profound.html
May 14, 2024
12
Choosing First-Line Systemic Therapy for Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
www.urotoday.com/journal/everyday-urology-oncology-insights/articles/117829-choosing-first-line-systemic-therapy-for-newly-diagnosed-mhspc.html
May 14, 2024
9
APCCC 2021: DNA Repair Defect Aberrations – What Are the Differences Between Them and What Is the Impact on Patient Management?
www.urotoday.com/conference-highlights/apccc-2021/133282-apccc-2021-dna-repair-defect-aberrations-what-are-the-differences-between-them-and-what-is-the-impact-on-patient-management.html
May 14, 2024
10
ASCO GU 2022: PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abiraterone as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135383-asco-gu-2022-propel-phase-iii-trial-of-olaparib-and-abiraterone-versus-placebo-and-abiraterone-as-first-line-therapy-for-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc.html
May 14, 2024
13
ASCO GU 2022: ARASENS Trial Overall Survival With Darolutamide Versus Placebo in Combination With ADT and Docetaxel for mHSPC
www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135403-asco-gu-2022-overall-survival-with-darolutamide-versus-placebo-in-combination-with-androgen-deprivation-therapy-and-docetaxel-for-metastatic-hormone-sensitive-prostate-cancer-in-the-phase-3-arasens-trial.html
May 14, 2024
3
ASCO GU 2024: Phase 1b/2 Study of Pembrolizumab Plus Belzutifan and Belzutifan Alone in Patients with Docetaxel-treated mCRPC: KEYNOTE-365 Cohort J
omnivore.app/amyken/asco-gu-2024-phase-1-b-2-study-of-pembrolizumab-plus-belzutifan--18d4db75b40
Jan 28, 2024
omnivore.app-ESMO 2023 Invited Discussant More Than Therapy Alone.pdf
typeset.io/library/esmo2023-3pj4gedk/omnivore-app-esmo-2023-invited-discussant-more-than-therapy-n98omj8v
Nov 19, 2023
1
(3) 【张捷聊教育】美国重提学徒制与AI时代的知识私有 - YouTube
www.youtube.com/watch?v=udhQClPZ3Ok
Nov 14, 2023
1
(3) Cubox AI Reading Assistant - YouTube
www.youtube.com/watch?v=CAfwJcvvjnE
Nov 14, 2023
1
(3) Taking notes from YouTube videos in Obsidian - YouTube
www.youtube.com/watch?v=qjWq4ck2-0o
Nov 13, 2023
1
(3) Continence preserving Robotic Radical Prostatectomy (Hood Technique) - With audio | Surgical Videos - YouTube
www.youtube.com/watch?v=3-KDN6yfkU4
Nov 13, 2023
1
(2) Hood Technique - Robotic Radical Prostatectomy by Dr Ash Tewari - YouTube
www.youtube.com/watch?v=cO1PjfJydHo
Nov 13, 2023
1
你真的能区分临床中观察性研究与试验性研究吗？ - 爱科学
www.iikx.com/news/statistics/1578.html
Nov 10, 2023
1
图说临床研究如何分类
www.ttdoc.cn/article/266.jhtml
Nov 10, 2023
8
ESMO 2023: ARASTEP: Darolutamide + ADT in Patients with High-Risk BCR Prostate Cancer – A Phase 3 Study
www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-prostate-cancer/147468-esmo-2023-tip-arastep-darolutamide-adt-in-patients-with-high-risk-bcr-of-prostate-cancer-a-phase-3-randomized-double-blind-placebo-controlled-study.html
Nov 4, 2023
1
ESMO 2023: ARASTEP: Darolutamide + ADT in Patients with High-Risk BCR Prostate Cancer – A Phase 3 Study
omnivore.app/amyken/esmo-2023-arastep-darolutamide-adt-in-patients-with-high-risk-bc-18b7ab9f269
Nov 4, 2023
1
Chronic Glucocorticoid Use and Risk for Advanced Prostate Cancer at Presentation: A SEER-Medicare Cohort Study.
omnivore.app/amyken/chronic-glucocorticoid-use-and-risk-for-advanced-prostate-cancer-18b22b1bc90
Oct 13, 2023
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer.
omnivore.app/amyken/discovery-of-bwa-522-a-first-in-class-and-orally-bioavailable-pr-18a95808fb1
Sep 19, 2023
1
2020_Suzuki et al_Comparison of the Perioperative and Postoperative Outcomes of Ileal Conduit and.pdf
typeset.io/library/shu-niao-guan-zao-kou-1vw1ka7g/2020-suzuki-et-al-comparison-of-the-perioperative-and-2d86cjsf
Jul 9, 2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma
www.practiceupdate.com/c/151207/67/25/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_blc&elsca4=blc&elsca5=newsletter&rid=OTczNzE3ODE2ODYS1&lid=37818878
May 5, 2023
2
7 Ways to Retain More of Every Book You Read
jamesclear.com/reading-comprehension-strategies
Apr 22, 2023
4
2023版CSCOPC指南更新——循证指引mHSPC治疗新时代_研究_负荷_患者
www.sohu.com/a/648453046_121119268
Apr 20, 2023
1
EAU 2023: Is There a Role for Local Therapy to the Bladder in Patients with Oligometastatic Disease?
www.urotoday.com/conference-highlights/eau-annual-congress-2023/eau-2023-bladder-cancer/143146-eau-2023-is-there-a-role-for-local-therapy-to-the-bladder-in-patients-with-oligometastatic-disease.html
Mar 26, 2023
11
Glasp Vs Readwise. Which Knowledge Management Tool is Better?
www.hongkiat.com/blog/glasp-vs-readwise/
Mar 26, 2023
1
ASCO 2019: Alliance A031201: A Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone, and Prednisone for Metastatic Castration Resistant Prostate Cancer - Medical Oncologist Perspective
www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-prostate-cancer/112895-asco-2019-alliance-a031201-a-phase-iii-trial-of-enzalutamide-versus-enzalutamide-abiraterone-and-prednisone-for-metastatic-castration-resistant-prostate-cancer.html
Oct 31, 2022
2
[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions]
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/97191-neuroendocrine-prostate-cancer-natural-history-molecular-features-therapeutic-management-and-future-directions.html
Oct 12, 2022
1
ASCO 2022: Radiographic Progression in the Absence of PSA Progression in Patients with mHSPC: Post Hoc Analysis of ARCHES
www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137711-asco-2022-radiographic-progression-in-the-absence-of-psa-progression-in-patients-with-mhspc-post-hoc-analysis-of-arches.html
Jul 8, 2022
1
Cubox 个人碎片知识库
cubox.pro/my/card?id=ff80808181ae5ebd0181c9574a217e94
Jul 4, 2022
Predictive Value of Isolated High-Grade Prostatic Intraepithelial Neoplasia in Detecting Clinically Significant Prostate Cancer Risk
www.practiceupdate.com/c/136097/1/3/?elsca1=emc_enews_expert-insight&elsca2=email&elsca3=practiceupdate_uro&elsca4=urology&elsca5=newsletter&rid=OTczNzE3ODE2ODYS1&lid=20845153
Jul 4, 2022
6